Abstract Sorafenib has been shown to be active in AML patients with FLT3-ITD. However, the effect of sorafenib in AML patients with FLT-TKD has never been well determined. Moreover, acquisition of secondary FLT3 TKD mutations, mainly at D835 (D835F/H/V/Y), are recognized as the major mechanisms of resistance of AML patients with FLT3-ITD to sorafenib. It has been reported that sorafenib induced death of cells that expressed the FLT3-ITD or FLT3-D835G but not cells that expressed the FLT3-D835Y point mutant or wild-type FLT3 in vitro. Here, we report the successful complete remission induction by sorafenib monotherapy in a FLT3-D835Y-positive patient with refractory AML-M5 followed by allogeneic stem cell transplantation.
Introduction
Activating mutations of the FMS-like tyrosine kinase-3 gene (FLT3) are one of the most frequent somatic alterations in acute myeloid leukemia (AML), occurring in approximately one-third of patients. FLT3 mutations consist of two major types: internal tandem duplication (ITD) mutations of the juxtamembrane region (head-to-tail duplication of 3-400 base pairs in exons 14 or 15) and point mutations involving the D835/I836 residues and others of the tyrosine kinase domain (TKD) [1, 2] . The FLT3-TKD mutations are reported to occur in approximately 7 % of patients, although they do not have a characteristic clinical signature [2, 3] . The FLT3-ITD mutations have been detected in about 23 % of patients with AML in several large studies and are associated with an increased risk of relapse and a shorter overall survival (OS) [4] .
Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), with activity against RAF kinases, KDR receptors, FLT3, PDGFR receptors, KIT, and RET kinase. [5] Sorafenib has been shown to be effective in FLT3-ITD mutated AML, alone or in addition to other cytotoxicity drugs. [6] [7] [8] [9] Most AML patients with FLT3-ITD show an initial clinical response to sorafenib, followed by the development of resistance within a few months to a year of treatment. [10, 11] One of the most common mechanisms of resistance to FLT3 inhibitors is the acquisition of secondary FLT3-TKD mutations, especially amino acid exchanges at residue D835 (D835F/H/V/Y). [10, 11] Up to now, the effect of sorafenib in AML patients with FLT3-TKD has never been widely investigated. Here, we report the successful complete remission induction by sorafenib monotherapy in a FLT3-D835Y-positive patient with refractory AML prior to allogeneic stem cell transplantation ( Fig. 1 
Discussion
Sorafenib has been shown to be active in AML patients with FLT3-ITD. However, the effect of sorafenib in AML patients with FLT-TKD has never been well determined. Moreover, acquisition of secondary FLT3-TKD mutations, mainly at D835 (D835F/H/V/Y), are recognized as the major mechanisms of resistance of AML patients with FLT3-ITD to sorafenib. [10, 11] It has been reported that sorafenib induced death of cells that expressed the FLT3-ITD or FLT3-D835G but not cells that expressed the FLT3-D835Y point mutant or wild-type FLT3 in vitro. [12] However, we report here the successful complete remission induction by sorafenib monotherapy in a FLT3-D835Y-positive patient with refractory AML-M5 followed by allogeneic stem cell transplantation. Though duration of sorafenib was quite short, it is hard to achieve completion remission for him only with the late effect of previous combined chemotherapies. According to the NCCN guidelines 2014, he may have experienced induction failure. Therefore, sorafenib may have taken some work for the complete remission of the patient. Taken together, our data call for closer examination of effect of the sorafenib in AML patients with FLT3-TKD mutation within a wider scale. 
